Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2022
June 2022, Vol 13, No 3
June 2022, Vol 13, No 3
Neoadjuvant Chemoimmunotherapy May Be New Standard of Care for Patients with Resectable NSCLC
By
Phoebe Starr
AACR Meeting Highlights
June 2022, Vol 13, No 3
The phase 3 CheckMate-816 trial establishes a new standard of care for resectable non–small-cell lung cancer (NSCLC): neoadjuvant nivolumab (Opdivo) plus chemotherapy.
Read More
Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
By
Wayne Kuznar
Prostate Cancer
June 2022, Vol 13, No 3
Treatment with the androgen receptor inhibitor darolutamide (Nubeqa), in combination with androgen-deprivation therapy (ADT) and docetaxel, significantly improved overall survival (OS) compared with ADT and docetaxel alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to recent results from the phase 3 ARASENS clinical trial, which were simultaneously published in the New England Journal of Medicine.
Read More
TOPAZ-1: Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Cholangiocarcinoma
June 2022, Vol 13, No 3
The global, double-blind, placebo-controlled, phase 3 TOPAZ-1 clinical trial evaluated the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab (Imfinzi) plus gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Read More
Peptide-Based CoVac-1 Vaccine Shows Promise Against COVID-19 in Patients with Cancer
By
Phoebe Starr
AACR Meeting Highlights
June 2022, Vol 13, No 3
A team of researchers in Germany has developed a multipeptide COVID-19 vaccine that boosts immunity in immunocompromised patients, according to results of a phase 1/2 trial reported at the 2022 American Association for Cancer Research annual meeting.
Read More
Kymriah Receives Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma
FDA Approvals, News & Updates
June 2022, Vol 13, No 3
On May 27, 2022, the FDA accelerated the approval of a new indication for the CD19-directed CAR T-cell therapy tisagenlecleucel (Kymriah; Novartis) for adults with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy.
Read More
Tibsovo Receives a New Indication, in Combination with Vidaza, for Newly Diagnosed Patients with AML and IDH1 Mutation
FDA Approvals, News & Updates
June 2022, Vol 13, No 3
On May 25, 2022, the FDA accelerated the approval of ivosidenib tablets (Tibsovo; Servier Pharmaceuticals), in combination with azacitidine tablets (Onureg; Celgene) for newly diagnosed acute myeloid leukemia (AML) and a susceptible
IDH1
mutation, as detected by an FDA-approved test, in patients aged ≥75 years, or patients with comorbidities that preclude the use of intensive induction chemotherapy.
Read More
Vidaza Now Approved for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
FDA Approvals, News & Updates
June 2022, Vol 13, No 3
On May 20, 2022, the FDA accelerated the approval of a new indication for azacitidine injection (Vidaza; Celgene) for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML).
Read More
FDA Grants Enhertu Regular Approval for Patients with Unresectable or Metastatic Breast Cancer
FDA Approvals, News & Updates
June 2022, Vol 13, No 3
On
May 4, 2022
, the FDA granted a regular full approval for fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo), an
HER2
-directed antibody and topoisomerase inhibitor conjugate, for the treatment of adults with unresectable or metastatic
HER2
-positive breast cancer who had received a prior anti–
HER2
-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and who had developed disease recurrence during or within 6 months of completing therapy.
Read More
Yescarta First CAR T-Cell Therapy FDA Approved for Patients with Large B-Cell Lymphoma
FDA Approvals, News & Updates
June 2022, Vol 13, No 3
On April 1, 2022, the FDA accelerated the approval of a new indication for the CAR T-cell therapy axicabtagene ciloleucel (Yescarta; Kite Pharma) for adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.
Read More
Genetic Score Makes PSA Screening More Accurate
By
Phoebe Starr
Prostate Cancer
June 2022, Vol 13, No 3
The use of a polygenic score (PGS) based on noncancer genetic variations in prostate-specific antigen (PSA) values helped to refine PSA screening in a large group of men without prostate cancer at baseline. The use of the PGS to adjust PSA allows identification of aggressive versus low-risk prostate cancer and can potentially reduce unnecessary biopsies, said the lead investigator of a large genome-wide association study (GWAS) presented at the 2022 American Association for Cancer Research annual meeting.
Read More
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma